What is the primary purpose of the new Chicago facility?

The facility is an integrated hub for research, development, and manufacturing of gene delivery technologies, designed to shorten lead times and increase capacity for North American clients.

When is the facility expected to become operational?

Operations are scheduled to begin in 2027, with phased expansions planned thereafter.

What types of products will be manufactured at this site?

The center will produce plasmids, recombinant viral vectors, non-viral vectors, and genetically modified cells.

Why was Chicago chosen as the location?

Chicago was selected for its rapid growth as a life sciences hub, its central U.S. location, and its access to a highly skilled research workforce.

AI News NQ Analysis

VectorBuilder to Establish $50 Million Advanced Bio-Manufacturing and R&D Center in Chicago

NQ Score 81/100

AI Summary (NQ-processed)

VectorBuilder has announced a $50 million investment to build an integrated R&D and manufacturing center in Chicago, aimed at strengthening its North American supply chain and production capacity.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What is the primary purpose of the new Chicago facility?: A: The facility is an integrated hub for research, development, and manufacturing of gene delivery technologies, designed to shorten lead times and increase capacity for North American clients.
Q: When is the facility expected to become operational?: A: Operations are scheduled to begin in 2027, with phased expansions planned thereafter.
Q: What types of products will be manufactured at this site?: A: The center will produce plasmids, recombinant viral vectors, non-viral vectors, and genetically modified cells.
Q: Why was Chicago chosen as the location?: A: Chicago was selected for its rapid growth as a life sciences hub, its central U.S. location, and its access to a highly skilled research workforce.